Post date January 11, 2024 Experience Roche $295 million acquisition of LumiraDx's point of care technology platform We are advising Roche on the acquisition
Post date October 31, 2023 Experience GSK exclusive license agreement for HS-20089 with Hansoh Pharma We advised GSK on the transaction
Post date October 23, 2023 Experience Roche $7.1 billion acquisition of Telavant and rights to RVT 3101 from Roivant We are advising Roche on the acquisition
Post date September 19, 2023 Experience Marvell Technology $1 billion senior notes offering The senior notes are due 2029 and 2033
Post date September 18, 2023 Experience Intuit $4 billion notes offering The investment-grade offering comprises four tranches of notes
Post date September 5, 2023 Experience PracticeTek merger with Integrated Practice Solutions and related financing We advised Lightyear Capital and PracticeTek on the transaction to form a leading U.S. retail healthcare solutions provider
Post date July 28, 2023 Experience Immedica Pharma acquisition of pegzilarginase assets from Aeglea We advised Immedica on the transaction
Post date May 4, 2023 Experience Ocado Group acquisition of 6 River Systems We are advising Ocado Group on the transaction
Post date May 3, 2023 Experience Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen We are advising Cellular Biomedicine Group on the transaction
Post date April 4, 2023 Experience Natura $2.525 billion sale of Aesop to L’Oréal We are advising Natura on the transaction